Search results for "Phase"

showing 10 items of 6344 documents

Significance of I313V mutation of NLPR3 gene in two pediatric patients

2011

Results Both case #1 (M.T) and #2 (V.C) displayed a mild clinical phenotype (episodes of urticarial rash and arthralgia associated with elevation of acute phase reactants), compatible with FCAS and Muckle-Wells syndrome, respectively. Both patients displayed good response to NSAID and/or steroid on demand. Compared to HD controls, patients displayed enhanced and delayed IL1b secretion. This was accompanied by higher levels of lL1Ra and IL-6 without any significant differences in IL-8. Interestingly, parents carrying the mutation also displayed higher levels of secreted IL-1b compared to HD control group. Conclusion The I313V mutation is associated with a mild CAPS phenotype and with an incr…

medicine.medical_specialtyMutationlcsh:Diseases of the musculoskeletal systembusiness.industryAcute-phase proteinlcsh:RJ1-570lcsh:Pediatricsmedicine.disease_causePhenotypeRheumatologyEndocrinologyRheumatologyUrticarial rashInternal medicineOn demandPoster PresentationPediatrics Perinatology and Child HealthmedicineImmunology and AllergySecretionPediatrics Perinatology and Child Healthlcsh:RC925-935businessGenePediatric Rheumatology
researchProduct

Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study

2014

ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on gastric cancer cells, whereas it is only present on a fraction of healthy stomach cells. This may reduce the risk of target-related side effects. Single-agent IMAB362 appears safe in patients with advanced gastro-esophageal cancer (GEC) based on data from a phase I trial. Methods: This international, multicenter, non-randomized phase IIa study (NCT01197885) investigated the efficacy and safety of repeated doses of IMAB362 (300 and 600 mg/m2) in patients with metastatic, refractory/recurrent, CLDN18.2-positive GEC (i.e. cancer of the stomach, the lower esophagus and th…

medicine.medical_specialtyNauseabusiness.industryPhases of clinical researchHematologyEsophageal cancermedicine.diseaseChemotherapy regimenGastroenterologyOncologyResponse Evaluation Criteria in Solid TumorsInternal medicineAnesthesiamedicineVomitingProgression-free survivalmedicine.symptomAdverse effectbusinessAnnals of Oncology
researchProduct

New diagnostic possibilities in systemic neonatal infections: metabolomics

2014

Systemic neonatal infection is a serious complication in preterm and term infants and is defined as a complex clinical syndrome caused by bacteria, fungi and virus. Sepsis remains among the leading causes of death in both developed and underdeveloped countries above all in the neonatal period. Earlier diagnosis may offer the ability to initiate treatment to prevent adverse outcomes. There have been many studies on various diagnostic haematological markers like acute phase reactants, C-reactive protein, procalcitonin, interleukins and presepsin. However, there is still no single test that satisfies the criteria as being the ideal marker for the early diagnosis of neonatal sepsis. In this reg…

medicine.medical_specialtyNeonatal infections; metabolomicsNeonatal sepsisbusiness.industryAcute-phase proteinInfant NewbornObstetrics and Gynecologymedicine.diseaseProcalcitoninSingle testSepsisNeonatal infectionMetabolomicsSettore MED/38 - Pediatria Generale E SpecialisticaSepsisPediatrics Perinatology and Child HealthmedicineHumansMetabolomicsbusinessIntensive care medicineComplicationNeonatal infectionBiomarkers
researchProduct

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

2006

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up per…

medicine.medical_specialtyNeurologyMultiple SclerosisDermatologySeverity of Illness IndexInterferon beta • Multiple sclerosis • Phase IV • Odds ratioInternal medicineSeverity of illnessmedicineConfidence IntervalsHumansImmunologic FactorsMultiple sclerosiNeuroradiologyAnalysis of Variancemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingGeneral MedicineOdds ratioInterferon-betaOdds ratiomedicine.diseaseInterferon betaMagnetic Resonance ImagingConfidence intervalPsychiatry and Mental healthItalyPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)NeurosurgeryPhase IVbusinessFollow-Up Studies
researchProduct

Viability and function of the cryopreserved whole rat ovary: comparison between slow-freezing and vitrification

2011

Objective To investigate four different protocols for cryopreservation of the whole rat ovary with intact vasculature to evaluate whether differences exist in post-thawing viability of the ovary after either vitrification or slow freezing. Design Experimental study. Setting Obstetrics and gynecology department. Animal(s) Immature Sprague-Dawley female rats. Intervention(s) Ovaries were isolated with the vascular tree intact up to the bifurcation of the abdominal aorta and were subsequently cannulated. The ovaries were flushed with increasing concentrations of the cryoprotectant dimethyl sulfoxide (DMSO) to either 1.5 or 7 M. The ovaries underwent cryopreservation by vitrification or passive…

medicine.medical_specialtyNeutral redTime FactorsCryoprotectantApoptosisOvaryBiologyCryopreservationRats Sprague-DawleyTissue Culture TechniquesAndrologychemistry.chemical_compoundCryoprotective AgentsOvarian FollicleFreezingFollicular phasemedicineAnimalsDimethyl SulfoxideVitrificationIncubationCryopreservationTissue SurvivalGynecologyDose-Response Relationship DrugEstradiolCaspase 3Dimethyl sulfoxideOvaryFertility PreservationObstetrics and GynecologyOrgan PreservationImmunohistochemistryVitrificationRatsPerfusionmedicine.anatomical_structureReproductive MedicinechemistryFemaleFertility and Sterility
researchProduct

Poster session 6. Phase 1 studies

2013

medicine.medical_specialtyOncologybusiness.industrymedicinePhase (waves)Medical physicsHematologySession (computer science)businessAnnals of Oncology
researchProduct

Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable co…

1991

Several phase III clinical trials demonstrated that hepatic arterial chemotherapy for unresectable colorectal liver metastases is able to provide significantly higher response rates than those obtained by systemic route: in more than 500 patients collected from 6 randomized trials, the median values of objective response rates were 55% after fluoxuridine (FUdR) continuous hepatic arterial infusion (HAI) vs. 18.5% after FUdR or 5-fluorouracil (5-FU) intravenous (i.v.) chemotherapy. Furthermore, the majority of those studies reported that median survival increased in the patient subgroups treated with intrahepatic chemotherapy, even if not always statistically significant [1-6]. Certainly, FU…

medicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchRectumGastroenterologyMetastasisHepatic arterial infusionInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialCisplatinChemotherapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateClinical trialmedicine.anatomical_structureOncologyFluorouracilDrug EvaluationSurgeryFluorouracilColorectal NeoplasmsFloxuridinebusinessmedicine.drugJournal of Surgical Oncology
researchProduct

Protandric hermaphrodite peculiarities in Amphiprion frenatus Brevoort (Teleostei, Pomacentridae)

1990

Electron microscopy of the male phase of the ovotestis of Amphiprion frenatus, a protandric hermaphrodite, showed no connective tissue between male and female areas and, as the basal lamina was lacking both along the seminiferous tubules and round the previtellogenic oocytes, the male and female germ cells were only separated by their respective surrounding somatic cells (Sertoli and follicle cells). Besides previtellogenic oocytes, oocytes in meiotic prophase and very small (young) previtellogenic oocytes, were detected in the ovarian part, as spermatogenesis proceeded, revealing oogenetic activity. Degeneration of some previtellogenic oocytes and their follicle cells was discernible.

medicine.medical_specialtyOvotestisSomatic cellAquatic ScienceBiologyAndrologyFollicleProphasemedicine.anatomical_structureEndocrinologyHermaphroditeMeiosisInternal medicinemedicineBasal laminaSpermatogenesisEcology Evolution Behavior and SystematicsJournal of Fish Biology
researchProduct

Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up M. Stahl, W. Budach, H.-J. Meyer & A. Cervantes On behalf of the ESMO Guidelines Working Group* Department of Medical Oncology and Centre of Palliative Care, Kliniken Essen-Mitte, Essen; Department of Radiation Oncology, University of Dusseldorf, Dusseldorf; Department of Surgery, Stadt Klinikum Solingen, Germany; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careEsophageal NeoplasmsMeta-Analysis as TopicRadiation oncologymedicineHumansNeoplasm MetastasisNeoplasm StagingEsophageal diseasebusiness.industryIncidenceGeneral surgeryFollow up studiesCancerHematologyEsophageal cancermedicine.diseasehumanitiesSurgeryEsophagectomyEuropeClinical PracticeTreatment OutcomeClinical Trials Phase III as TopicOncologyDiagnosis treatmentEsophagoscopybusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Establishment and Characterization of a Continuous Human Chondrosarcoma Cell Line, ch-2879: Comparative Histologic and Genetic Studies with Its Tumor…

2003

Chondrosarcomas are malignant cartilage-forming tumors that represent the second most common malignant solid tumor of bone. These biologically poorly understood neoplasms vary considerably in clinical presentation and biologic behavior. Chemotherapy and radiation therapy are generally ineffective. Here we describe the establishment and characterization of a new human chondrosarcoma cell line named ch-2879, and we compare the cell line with its tumor of origin. The cell line was established from a recurrent grade 3 chondrosarcoma of the chest wall and characterized by growth kinetics and morphologic studies. Immunocytochemistry and RT-PCR were performed to examine the expression of cartilage…

medicine.medical_specialtyPathologyPopulationCell Culture TechniquesChondrosarcomaBone NeoplasmsChromosomal translocationVimentinPathology and Forensic MedicineCyclin D1Tumor Cells CulturedmedicineHumanseducationMolecular BiologyMetaphaseChromosome Aberrationseducation.field_of_studymedicine.diagnostic_testbiologyCytogeneticsKaryotypeCell BiologyFlow Cytometrymedicine.diseaseMicroscopy ElectronKaryotypingbiology.proteinCancer researchChondrosarcomaFluorescence in situ hybridizationLaboratory Investigation
researchProduct